Bone Metastasis Market

Market Overview

The global bone metastasis market size was valued at USD 19.7 billion in 2022. It is projected to reach USD 39.7 billion by 2031, growing with a CAGR of 8.1% during the forecast period (2023–2031).

Cancers such as prostate, breast, and lung are most likely to spread to the bone. The spread of any type of cancer to bone can result in severe pain, hypercalcemia, fracture, and spinal cord or nerve root compression. According to the Modern Medicine Network, approximately 30% to 60% of patients with advanced lung cancer develop bone metastases. Bone pain, shattered bones, urine and bowel incontinence, weakness in the arms or legs, and elevated blood calcium levels (hypercalcemia), which can result in nausea, vomiting, constipation, and confusion, are some of the symptoms of bone metastasis. Almost all cancers have the potential to spread to the bones. However, some cancers, including breast and prostate cancer, move quickly to the bones. People with cancer who received an early diagnosis of the disease often develop bone metastases. Additionally, bone metastasis is more likely to develop in cancer patients with advanced stages of the disease. Any bone can have bone metastases, although the spine, pelvis, and thighs are the most frequently affected.

Bone Metastasis treatment is rarely curative, but by utilizing systemic anticancer medications against a background of multimodal supportive care, disease control is frequently achievable for many years. This care entails the use of local treatments like radiation therapy, orthopedic surgery, and specialized palliative care, as well as bone-targeted drugs like bisphosphonates or denosumab to inhibit tumor-associated osteolysis and prevent skeletal morbidity to lessen the effects of metastatic bone disease on bodily functions.

Market Dynamics

What are the factors driving the market growth?

High Prevalence of Cancer

The high prevalence and rising incidence rates of the causes of bone metastasis, especially breast cancer and prostate cancer, are the main factors driving the global market for treatments for bone metastasis. The World Health Organization (WHO) estimates that more than 2.1 million women receive a breast cancer diagnosis each year. Approximately 1,276,106 new cases of prostate cancer were reported globally in 2018, according to Globocan. As a result, one of the major reasons anticipated to propel the bone metastasis treatment market during the projected period is the high prevalence and rise in incidence rates of bone metastasis worldwide. Additionally, technical developments in the early diagnosis of bone metastases, the introduction of new products, and the development of products with a strong clinical trial pipeline are anticipated to fuel the market's expansion.

Advances in Technology

The quality of life and life expectancy of cancer patients are significantly impacted by bone metastases, which frequently cause excruciating pain, pathological fractures, and nerve damage. Surgery is still the gold standard for treating bone metastases, even though current therapeutic alternatives are typically just palliative and not curative. The main goal of surgical intervention is to replace the damaged bone with a bioimplant, which can be created using materials from various sources and manufactured using a variety of procedures that have developed over time in tandem with clinical requirements. Many researchers and medical professionals have sought to create biomaterials with potentially effective biological and mechanical properties. Major players in the market are researching to find effective and non-invasive treatments for bone metastasis.

Regional Analysis

The global bone metastasis market share is divided into four major regions such as North America, Europe, Asia-Pacific (APAC), Latin America, Middle East & Africa (LAMEA).

North America dominates the market due to the presence of a well-developed healthcare sector and the growing prevalence of breast cancer in the region. Consumption of highly processed foods, sugary beverages, obesity, Type 2 diabetes, sedentary lifestyle, and growing alcohol consumption have led to a rise in the cases of cancer in the region. Increasing research on cancer stem cells is anticipated to boost the market demand. Additionally, the growth of the regional market is boosted by the presence of major players like Merck & Co., Inc. and Pfizer, Inc. In addition to this, the manufacturers in the region are working on new, innovative products for the bone metastasis market. Therefore, the main factors driving the demand for the bone metastasis market in the forecast period include an expanding patient population, growing strategic alliances, increased R&D for new product releases, and rising incidence rates of bone metastasis disorders.

Europe is likely to stand second in the market owing to the increased prostate cancer, government support, and reimbursement policies in this region. According to Cancer Research U.K, in males, prostate cancer is the most common cancer, with around 47,200 new cases each year. Prostate cancer accounts for 26% of all new cancer cases in males in the UK. Early adoption of advanced medical technology for cancer diagnostics and high cancer awareness is projected to help the region’s market growth over the forecast period.

Asia Pacific is predicted to be the fastest-growing region. The presence of a developing healthcare sector and the growing prevalence of cancer are major drivers for market growth. Globally, there were 17.0 million instances of cancer and 9.5 million cancer-related deaths in 2018, according to estimates from the International Agency for Research on Cancer (IARC). Because of population expansion and aging, it is anticipated that by 2040 there will be 16.3 million cancer deaths and 27.5 million new cancer cases worldwide, with China representing most of the cancer burden. It is estimated that China alone accounts for 50% of all cancer cases in the Asia Pacific region. Other factors contributing to the market expansion in the area include an increase in the number of patients with bone metastases, government measures to increase awareness, and an increase in demand for the treatment. One of the other elements anticipated to favorably affect the growth of the bone metastasis market over the forecast period is the existence of a sizable population in the region.

Latin America, the Middle East, and Africa hold the least share; this is mainly due to the presence of poor economies, stringent government policies, and lack of healthcare services, especially in the African region. The Middle East holds the majority of the market share in the region due to the presence of a highly developed healthcare industry and significant healthcare spending by developed economies like Saudi Arabia, Kuwait, Dubai, and others in the region.

Segmental Analysis

The global bone metastasis market share is segmented by type, diagnosis, treatment, and end-user.

On the basis of type, the market is segmented into osteolytic bone metastasis, osteoblastic bone metastasis, mixed bone metastasis, and others.

Osteolytic bone metastasis is expected to be the leading segment during the forecast period. Osteolytic metastasis is the most frequent type of bone metastasis in cancer patients. Although local bone formation response can also be seen, the major lesion is lytic and destructive. Solid tumors such as breast cancer, prostate cancer, thyroid cancer, lung cancer, and renal cancer can develop osteolytic metastases. Additionally, multiple myeloma frequently results in significant bone destruction.

Osteosclerosis causes the production of new bone. Prostate cancer metastases are usually osteoblastic. Osteoblastic bone lesions are rare in other cancer types; however, they have been reported in, for example, colon, cervical and cervical cancer. During osteoblastic bone metastases, the balance between bone resorption and bone formation is tipped in favor of the latter. Patients suffer severe bone pain, and the poor quality of bone produced in osteoblastic bone metastases means that bone fractures are a common event.

Based on the diagnosis, the market is segmented into biopsy, blood test, imaging, and others.

A bone biopsy is a process in which bone samples are extracted (during surgery or with a specific biopsy needle) to check for the presence of cancer or other abnormal cells. In contrast to a bone marrow biopsy, which involves the innermost section of the bone, a bone biopsy involves the outer layers of the bone.

Imaging examinations are performed to look into symptoms and indicators that could point to bone metastasis. Tests may include X-ray, Bone scan,  Computerized tomography (CT), and Magnetic resonance imaging (MRI).

On the basis of treatment, the market is segmented into medical therapies, surgery, medication, and others.

Surgery can be used to fix fractured bones or stabilize bones that are at risk of breaking. Using metal plates, screws, and nails, surgeons can stabilize a bone that is in danger of shattering as a result of bone metastases. Orthopedic fixation can enhance functionality and relieve pain.

Chemotherapy, targeted therapy, hormone therapy, ablation therapy, and other therapies are sub-segmented under "medical therapies." The ablation therapy market is divided into cryoablation, radiofrequency ablation, and others. During the forecast period, the chemotherapy segment is anticipated to dominate the global market for bone metastasis treatment.

Based on the end-user, the market is segmented into hospitals & clinics, diagnostic centers, pharmacies, and ambulatory surgical centers.

Recent Developments

• June 2021- Bayer announced that it had reached a deal to purchase PSMA Therapeutics Inc. and Noria Therapeutics Inc. The acquisition increases the scope of Bayer's current oncology portfolio.
• March 2022- FDA approved Novartis Pluvicto as the first targeted radioligand therapy for the management of metastatic castration-resistant prostate cancer.